This meeting is restricted to healthcare professionals based outside of the United States. |
Saturday, June 4, 2011
Ballroom IV & V, Ballroom Level
Sheraton Chicago Hotel & Towers |
6.30 PM - 7.30 PM
Registration and Dinner
7.30 PM - 9.30 PM
Educational Session |
|
|
FACULTY |
|
James C. Yao, MD (Chair)
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Marianne Pavel, MD
Charité Hospital
Berlin, Germany
|
Ramon Salazar, MD, PhD
L'Hospitalet de Llobregat
Catalan Institute of Oncology
Barcelona, Spain
Marco Volante, MD, PhD
University of Turin
San Luigi Hospital
Turin, Italy |
|
AGENDA |
|
6.30 PM
|
Registration and dinner
|
|
7.30 PM
|
Welcome and introduction
James C. Yao, MD
|
|
7.45 PM
|
Histopathologic classification and staging: Have we underestimated NET’s malignant potential?
Marco Volante, MD, PhD
|
|
8.00 PM
|
The role of imaging and biomakers
Marianne Pavel, MD
|
|
8.15 PM
|
Historical management: Where are the unmet needs?
Ramon Salazar, MD, PhD
|
|
8.35 PM
|
Contemporary management: What have we learned from phase III trials?
James C. Yao, MD
|
8.55 PM
|
NET Quiz: What have you learned? |
|
9.15 PM
|
Questions and faculty panel discussion
James C. Yao, MD |
9.30 PM
|
Concluding remarks
James C. Yao, MD |
|
TARGET AUDIENCE |
This educational activity is intended for medical oncologists, radiation oncologists, endocrinologists, gastroenterologists, pulmonologists, pathologists, radiologists, surgeons, and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors. This meeting is restricted to healthcare professionals based outside of the United States.
|
 DISCLOSURE OF CONFLICTS OF INTEREST |
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of educational activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality educational activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
|
DISCLOSURE OF UNLABELED USE OF AGENTS | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food & Drug Administration or the European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
DISCLAIMER | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
LOCATION | Ballroom IV & V, Ballroom Level
Sheraton Chicago Hotel & Towers
301 East North Water Street
Chicago, Illinois 60611
Tel: +1.312.464.1000 |
GETTING TO THE SHERATON | The Sheraton Hotel & Towers is on shuttle route #4. The shuttle departs from McCormick Place Convention Center, South Bldg, Level 1, near Room S103. |
ORGANIZER |
This meeting is a prIME Oncology activity.
|
SUPPORT |
Support for this educational activity is provided by Novartis Oncology.
|
FEE INFORMATION | There is no fee for this activity. Dinner will be served. Preregistration is not required for this event; however space is limited. |
STATEMENT | Not an official event of the 2011 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation. |
|
